SAMSUNG-ELECTRONICS
9.9.2021 10:02:12 CEST | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today announced that four of its System LSI products received product carbon footprint label certification from the Carbon Trust, the first of Samsung’s logic chips to do so.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210909005409/en/
Having received the semiconductor industry’s first carbon footprint accreditation for memory chips from the Carbon Trust in 2019, Samsung has now broadened its ESG (Environmental, Social, and Governance) spectrum with this global recognition of ‘eco-friendly’ logic chips. Samsung also grabbed the industry’s first triple Carbon Trust Standard for Carbon, Water and Waste in June 2021.
The Carbon Trust is an independent and expert partner of organizations around the world that advises businesses on their opportunities in a sustainable, low carbon world. The Carbon Trust also measures and certifies the environmental footprint of organizations, supply chains and products.
Of the various certification categories of the Carbon Trust, Samsung’s System LSI products received the CO2 Measured product carbon footprint label. The label certifies the chip’s carbon footprint, which informs consumers of the impact that the product and its manufacturing process have on the environment.
Receiving the CO2 Measured label is a critical first step for carbon reduction, since it verifies the current carbon emissions of the product with globally recognized specifications (PAS 2050), which Samsung can use as a benchmark to measure future carbon reductions.
Correctly measuring the carbon footprint of a product requires extensive effort and time. It involves calculating the amount of carbon emitted from fabricating raw subsidiary materials and transporting the product, as well as the carbon emission from using electricity, water, and gas. The hundreds of fabrication processes needed to make a semiconductor chip adds to the complication.
“We’re pleased to have worked with Samsung on this step in its sustainability journey,” said Hugh Jones, managing director at the Carbon Trust Advisory. “The Carbon Trust’s Carbon Measured certification is a clear and credible indicator for consumers that the carbon footprint of these products have been independently verified, as well as a baseline for Samsung to compare against as they work towards reducing their emissions in the future.”
The four products to receive certification include a variety of Samsung’s System LSI chips, from mobile processors to image sensors. The Exynos 2100, one of the four products to receive certification, is a high-performance mobile processor built with the most advanced 5-nanometer (nm) extreme ultra-violet (EUV) process node. The 0.7-micrometer (μm)-pixel image sensor ISOCELL HM2, DTV SoC (S6HD820), and TCON (S6TST21) also received certification by the Carbon Trust.
Including the four chips, Samsung has so far received certifications for fourteen of its semiconductor products from the Carbon Trust.
“We are thrilled to be globally acknowledged for our eco-friendly efforts,” said Seong-dai Jang, senior vice president and head of DS Corporate Sustainability Management Office at Samsung Electronics. “We will continue to fulfill our carbon reduction goals and expand our efforts to a wider range of eco-friendly, high-performance products to meet the global standards for a sustainable future.”
Exynos 2100
Based on 5nm EUV process technology, the Exynos 2100 is Samsung’s first 5G-integrated flagship mobile processor for premium mobile devices. The Exynos 2100 performs up to 26-trillion-operations-per-second (TOPS) with more than twice the power efficiency than the previous generation.
ISOCELL HM2
The ISOCELL HM2 is a 0.7μm-pixel image sensor that opened up the market for ultra-high resolutions. The 108MP-sensor is around 15 percent smaller than the 0.8μm-based predecessors, and reduces the height of the camera module by 10 percent, while featuring faster autofocus, nine-pixel binning and 3x lossless zoom.
DTV SoC (S6HD820)
Samsung’s DTV SoC (S6HD820) is an essential component in television as picture quality evolves from 4K to 8K standard. The DTV SoC’s NPU (neural processing unit) allows AI technology to improve picture quality and audio processing.
TCON (S6TST21)
A TCON takes video data from the DTV SoC and converts it according to the demands of the DDI (Display Driver IC). The data transmission speed of the TCON is important when it comes to quickly transmitting high-resolution video data to the DDI. Samsung’s TCON (S6TST21) integrates two 8K 60-hertz (Hz) chips to minimize energy loss.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005409/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
